Brought to you by 
Blackstone launches Anthos with $250mm Series A financing
01 Mar 2019
Executive Summary
Cardiovascular disease-focused Anthos Therapeutics Inc. was launched with a $250mm Series A round from funds managed by PE firm Blackstone Life Sciences, which will control the company's pipeline development.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Blackstone launches Anthos with $250mm Series A financing
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice